Search research articles
Contact Us
Filters
Showing results (71-80 of 129) with videos related to
Page
of 13
Sort By:
Science & Medicine in Football
|
March 21, 2024
Understanding the role of gaze behaviour and coaching experience in the assessment of youth soccer teams
Jade O'Brien-Smith, Mitchell R Smith, Pieter Vansteenkiste, et al.
Oncotarget
|
July 15, 2024
Correction: Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics
Gaurav S Choudhary, Trinh T Tat, Saurav Misra, et al.
Cancer
|
September 30, 2004
Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma
Hossein Borghaei, Michael Millenson, Russell Schilder, et al.
Biology of Sport
|
September 4, 2020
Dribble Deficit quantifies dribbling speed independently of sprinting speed and differentiates between age categories in pre-adolescent basketball players
Daniele Conte, Aaron T Scanlan, Vincent J Dalbo, et al.
Leukemia Research
|
August 24, 2013
Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma
Danielle Shafer, Mitchell R Smith, Hossein Borghaei, et al.
British Journal of Haematology
|
May 3, 2016
Is rituximab sub-optimally dosed in indolent B cell lymphoma?
Yazeed Sawalha, Basel Rouphail, Xuefei Jia, et al.
Leukemia & Lymphoma
|
January 3, 2013
A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study
Francine M Foss, Nelida Sjak-Shie, Andre Goy, et al.
British Journal of Haematology
|
April 26, 2014
Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study
Andrew M Evens, Mitchell R Smith, Izidore S Lossos, et al.
Leukemia & Lymphoma
|
September 17, 2004
Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma
Dina Ibrahim, Mitchell R Smith, Mary Varterasian, et al.
Leukemia & Lymphoma
|
March 8, 2024
Lenalidomide, rituximab (R<sup>2</sup>), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma
Brian T Hill, Yanwen Chen, Deepa Jagadeesh, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 129) with videos related to
Sort By:
Page
of 13
Science & Medicine in Football
|
March 21, 2024
Understanding the role of gaze behaviour and coaching experience in the assessment of youth soccer teams
Jade O'Brien-Smith, Mitchell R Smith, Pieter Vansteenkiste, et al.
Oncotarget
|
July 15, 2024
Correction: Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics
Gaurav S Choudhary, Trinh T Tat, Saurav Misra, et al.
Cancer
|
September 30, 2004
Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma
Hossein Borghaei, Michael Millenson, Russell Schilder, et al.
Biology of Sport
|
September 4, 2020
Dribble Deficit quantifies dribbling speed independently of sprinting speed and differentiates between age categories in pre-adolescent basketball players
Daniele Conte, Aaron T Scanlan, Vincent J Dalbo, et al.
Leukemia Research
|
August 24, 2013
Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma
Danielle Shafer, Mitchell R Smith, Hossein Borghaei, et al.
British Journal of Haematology
|
May 3, 2016
Is rituximab sub-optimally dosed in indolent B cell lymphoma?
Yazeed Sawalha, Basel Rouphail, Xuefei Jia, et al.
Leukemia & Lymphoma
|
January 3, 2013
A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study
Francine M Foss, Nelida Sjak-Shie, Andre Goy, et al.
British Journal of Haematology
|
April 26, 2014
Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study
Andrew M Evens, Mitchell R Smith, Izidore S Lossos, et al.
Leukemia & Lymphoma
|
September 17, 2004
Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma
Dina Ibrahim, Mitchell R Smith, Mary Varterasian, et al.
Leukemia & Lymphoma
|
March 8, 2024
Lenalidomide, rituximab (R<sup>2</sup>), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma
Brian T Hill, Yanwen Chen, Deepa Jagadeesh, et al.
Page
of 13